- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07558252
The Effect of Acupressure on Multiple Sclerosis Patients (MS)
23. april 2026 opdateret af: Mustafa Karaağaç, Hasan Kalyoncu University
The Effect of Acupressure on Pain, Fatigue, Sleep, and Quality of Life in Multiple Sclerosis Patients
There are studies in the literature evaluating the effects of acupressure application in MS patients.
In a study; it was shown that acupressure application reduced pain and fatigue.
In a study; acupressure was found to reduce fatigue and depression scores.
In a study; acupressure was found to improve the patient's physical and cognitive functions and quality of life.
In a study; acupressure was found to have positive effects on reducing fatigue in MS patients.
In a study acupressure application was found to have significant effects in reducing fatigue.
There are no studies evaluating the combined effects of acupressure on fatigue, pain, sleep quality, and quality of life parameters in MS patients.
This study is planned to determine the effects of acupressure on fatigue, pain, sleep quality, and quality of life in MS patients.
Studieoversigt
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
90
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Şanlıurfa
-
Sanliurfa, Şanlıurfa, Tyrkiet (Türkiye), 63000
- Hospital of Harran University
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- At least 6 months of confirmed MS diagnosis
- With RRMS
- Aged 18 years or older
- With a pain score of VAS≥3
- Not having used pain medication in the last 8 hours prior to the acupressure session
- With a Fatigue Severity Scale score of 4 or higher
- Without a diagnosis of cancer
- Without diabetes
- No neurological disease other than MS
- Not receiving any other complementary treatment
- Non-smoker
- Literate and able to communicate
- No deformity or lesion in the areas where acupressure will be applied
- No mental problems that could prevent cooperation with the acupressure application
- Not taking sedative medication
- With stable vital signs
- Without heart disease
- Not pregnant
- Residing in Şanlıurfa
- Patients who are willing to participate in the study
Exclusion Criteria:
- Patients who did not attend at least 4 sessions
- Patients who wish to withdraw from the study
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Styring
|
|
|
Eksperimentel: intervention
|
examining pain, fatigue, sleep, and quality of life
|
|
Sham-komparator: sham
Plasebo
|
examining pain, fatigue, sleep, and quality of life
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Fatigue Severity Scale (FSS)
Tidsramme: Baseline, at the end of the 3rd week, and at the end of the 6th week.
|
The FSS is a 9-item scale used to assess the impact of fatigue on daily activities.
Each item is rated on a 7-point Likert scale ranging from 1 to 7. The total score is the average of the 9 items.
Scores range from 1 to 7, where higher scores indicate greater fatigue severity (worse outcome).
|
Baseline, at the end of the 3rd week, and at the end of the 6th week.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Visual Analog Scale (VAS) for Pain
Tidsramme: Baseline, at the end of the 3rd week, and at the end of the 6th week.
|
The Visual Analog Scale (VAS) is used to measure the intensity of pain.
It consists of a 10-cm horizontal line where 0 indicates "no pain" and 10 indicates "unbearable pain."
Participants mark the point that represents their current pain level.
Higher scores represent increased pain intensity (worse outcome).
|
Baseline, at the end of the 3rd week, and at the end of the 6th week.
|
|
Pittsburgh Sleep Quality Index (PSQI)
Tidsramme: Baseline, at the end of the 3rd week, and at the end of the 6th week.
|
The PSQI is used to evaluate sleep quality over the past month.
It consists of 19 individual items generating seven component scores.
The total score ranges from 0 to 21.
A higher total score indicates poorer sleep quality (worse outcome).
|
Baseline, at the end of the 3rd week, and at the end of the 6th week.
|
|
Multiple Sclerosis Quality of Life-54 (MSQOL-54)
Tidsramme: Baseline, at the end of the 3rd week, and at the end of the 6th week.
|
The MSQOL-54 is a multidimensional health-related quality of life measure.
It provides two main summary scores: Physical Health and Mental Health.
Scores for each subscale are transformed to a 0-100 scale.
For these subscales, higher scores indicate a better quality of life (better outcome).
|
Baseline, at the end of the 3rd week, and at the end of the 6th week.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. marts 2025
Primær færdiggørelse (Faktiske)
1. november 2025
Studieafslutning (Faktiske)
1. april 2026
Datoer for studieregistrering
Først indsendt
7. april 2026
Først indsendt, der opfyldte QC-kriterier
23. april 2026
Først opslået (Faktiske)
30. april 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
30. april 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
23. april 2026
Sidst verificeret
1. april 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Demyeliniserende autoimmune sygdomme, CNS
- Autoimmune sygdomme i nervesystemet
- Demyeliniserende sygdomme
- Multipel sclerose
- Terapeutik
- Komplementære terapier
- Fysioterapimodaliteter
- Rehabilitering
- Terapi, blødt væv
- Muskuloskeletale manipulationer
- Akupressur
Andre undersøgelses-id-numre
- 2025/016
- Non (Anden identifikator: Non)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Multipel sclerose
-
Baskent UniversityIkke rekrutterer endnuMULTIPL SKLEROSETyrkiet (Türkiye)
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeKlassisk Hodgkin lymfom | Lymfocytrigt klassisk Hodgkin-lymfom | Ann Arbor Stage IB Hodgkin lymfom | Ann Arbor Stage II Hodgkin lymfom | Ann Arbor Stage IIA Hodgkin lymfom | Ann Arbor Stage IIB Hodgkin lymfom | Ann Arbor Stage I Hodgkin lymfom | Ann Arbor Stage I Mixed Cellularity Klassisk Hodgkin-lymfom og andre forholdForenede Stater